CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells
International Journal of Molecular Sciences · 23.05.2025 · 26 (11) · 5024
DOI: 10.3390/ijms26115024 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.05.2025. Verfasst von Alexandra von Jutrzenka-Trzebiatowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, Saxon State Ministry for Science, Culture and Tourism, Else Kröner-Fresenius-Stiftung.
Abstract (Originalsprache)
The Reverse Chimeric Antigen Receptor (RevCAR) system is an adapter CAR T cell technology that allows the precise tuning of T cell activity and, thus, improved safety management. RevCAR T cells recognize and eradicate tumor cells via a bispecific adapter molecule, termed the RevCAR Target Module (RevTM). To further reduce the risk of on-target off-tumor toxicities, Dual-RevCAR T cells can be employed. These cells harbor two different RevCAR constructs, with the signaling domain of either CD3zeta or CD28. Therefore, Dual-RevCAR T cells only exert their full function when both RevCAR constructs are triggered simultaneously upon recognition of two different tumor antigens via RevTMs, enabling a precise AND-gate targeting approach and rendering them highly interesting for clinical application. For this purpose, standardized and reproducible clinical-grade cell manufacturing is required, for which the CliniMACS Prodigy can be used. Here, we present that automated processing of RevCAR and Dual-RevCAR T cells via the CliniMACS Prodigy results in potent expansion, strong transduction, and a favorable phenotype for clinical application. Moreover, obtained cell products were highly functional in a strict RevTM-dependent manner for both monospecific and AND-gate targeting, clearly underlining their high potential for clinical application against various tumor entities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany.
- Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany.
- National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-R…
- German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
ORCID-Profile: Rutuja Gupte, Claudia Arndt, Michael Bachmann
Förderung
- Federal Ministry of Education and Research
- Saxon State Ministry for Science, Culture and Tourism
- Else Kröner-Fresenius-Stiftung
- Federal Ministry of Education and Research (BMBF
Zitieren
APA
von Jutrzenka-Trzebiatowski, A., Gupte, R., Daglar, C., Berndt, N., Arndt, C., Bachmann, M., & Feldmann, A. (2025). CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells. International Journal of Molecular Sciences, 26(11), 5024. https://doi.org/10.3390/ijms26115024
Vancouver
von Jutrzenka-Trzebiatowski A, Gupte R, Daglar C, Berndt N, Arndt C, Bachmann M, et al. CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells. International Journal of Molecular Sciences. 2025;26(11):5024. doi:10.3390/ijms26115024
BibTeX
@article{vonJutrzenkaTrzebiatowski2025,
author = {von Jutrzenka-Trzebiatowski, Alexandra and Gupte, Rutuja and Daglar, Cansu and Berndt, Nicole and Arndt, Claudia and Bachmann, Michael and Feldmann, Anja},
title = {CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5024},
doi = {10.3390/ijms26115024}
}
EUVIMED